Key Highlights

  • Autonomix Medical (NASDAQ:AMIX) finished Tuesday, November 10, 2026 at USD 2.58, a rise of 51.76% from a calculated prior close of USD 1.70, or USD 0.88 per share, placing it among the biggest gainers in a published screener snapshot of 4,625 names.
  • Trading reached 48.46 million shares at a relative Volume of 522.06, which points to a typical average near 92,826 shares a day (calculated), compared with 342,889 shares traded on November 9.
  • Market Capitalization is USD 5.06 million on about 1.96 million shares (calculated), up from roughly USD 3.33 million at the prior close, and the 52-week range runs from USD 1.46 to USD 32.55.
  • Trailing diluted EPS is USD -46.48, EPS growth is +64.78%, there is no P/E, the Dividend Yield is 0.00%, and cash stood at USD 9.9 million on December 31, 2025.

What Drove Autonomix Medical on November 10 (+51.76%)

The shares closed the regular session at USD 2.58, up USD 0.88 from a calculated prior close of USD 1.70 on Monday, November 9, 2026. A pre-market review earlier that morning showed an indication of USD 1.87, up 10.00%, so the close lands USD 0.71, or 38.0%, over that indication (calculated). The stock had already climbed 11.84% on November 9 within a range of USD 1.53 to USD 1.77. The 48.46 million shares traded is about 141 times the 342,889 from November 9 and about 24.7 times the whole share count (both calculated). Turnover at that scale means every holder could in theory have traded more than once during the day.

The Rationale: No Catalyst Identified in Published Coverage

Two searches found no company release or filing dated November 9 or 10, 2026, so published coverage leaves the cause unidentified. The most recent items located were from September 30, 2026, when the company reported FDA pre-submission feedback backing a 510(k) pathway for its standalone catheter device, and from early October 2026, when it announced a Canadian patent. As general context, pre-revenue device companies often leap on regulatory headlines, financing, short covering or Social Media attention, and a 51.76% move on a 1.96 million share base takes comparatively little capital. Published summaries show two analysts rating the stock Buy with an average target of USD 40.80, a figure that trading has not tested.

Valuation, Liquidity and Risks for Autonomix Medical (NASDAQ:AMIX)

At USD 2.58, the USD 5.06 million Market Value equals about 0.51 times the USD 9.9 million of cash reported on December 31, 2025 (calculated), though the company has spent cash since and may have raised funds that this review could not confirm. The close is 92.1% under the 52-week high of USD 32.55 and 76.7% over the low of USD 1.46 (calculated). The company estimates it requires a further USD 30 million to USD 36 million to reach commercialization of its first indication, so offerings, warrants or a reverse split are the main dilution risks. With fewer than 2 million shares, a few trades can shift the price and spreads may be wide. Gains this size often reverse. Nothing here suggests the move will continue.

Where Things Stand

Autonomix Medical (NASDAQ:AMIX) climbed 51.76% to USD 2.58 on November 10, 2026 on 48.46 million shares, and published coverage shows no catalyst. The stock had risen 11.84% the day before and was indicated 10.00% higher before the open, so momentum and scarce Supply are the likeliest general mechanics, not confirmed causes. Funding needs of USD 30 million to USD 36 million and dilution risk remain the main constraints.